An observational study in Shoulder Osteoarthritis and Shoulder Arthritis, sponsored by Smith & Nephew, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-07.
Sponsored by Smith & Nephew, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Osteoarthritis by Smith & Nephew, Inc. — 2 open to participants now, 7 under way, none of them phase 3. Osteoarthritis · Smith & Nephew, Inc..
Among the 41 studies in Osteoarthritis by Smith & Nephew, Inc., this one is the 4th largest by planned enrollment of the 24 observational ones that give a count, is one of 2 that started in 2024, is one of 24 observational ones, and was the 39th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →2 of the 41 studies in Osteoarthritis by Smith & Nephew, Inc. are open now, in 1 country. Recruiting first, the newest first:
Smith & Nephew, Inc. · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 220 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.
Median enrollment 78 across the 17 interventional studies, 131 across the 24 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Smith & Nephew, Inc. is the lead sponsor of 134 studies on the registry; 11 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
1 of the studies in Osteoarthritis by Smith & Nephew, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06319911Smith & Nephew, Inc.AETOS Shoulder System | 2027-08-30 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Osteoarthritis by Smith & Nephew, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to confirm the safety and performance of the AETOS Shoulder System for USA adoption. This is a prospective, open, adaptive, non-comparative, multi-centre investigation enrolling a maximum of 220 subjects in 2 cohorts (anatomic and reverse) at up to 15 sites. No intra-study comparator group will be included, and there will be no randomization
This study will confirm the safety and performance of the AETOS Shoulder System in anatomic and reverse TSA. Revisions will not be enrolled into this study.
The AETOS Shoulder System is manufactured by Smith \& Nephew, Inc., 1450 Brooks Road Memphis, Tennessee 38116 USA, and has been 510k Cleared as of 07Jun2023; therefore, it is considered a post-market product and will be procured through normal commercial channels in the USA. The humeral stem is designed to be used for both Total Shoulder Arthroplasty (TSA) and reverse shoulder arthroplasty procedures. The humeral stems are designed with fins and a porous plasma coating to provide fixation within the proximal humeral metaphysis.
Males and females who are at least 18 years of age at the time of consent, are skeletally mature, and are indicated for primary anatomic or primary reverse will be enrolled in the study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all the following criteria to be included in the study:
Patient is undergoing a primary elective anatomic or reverse shoulder replacement surgery for one of the following indications:
-
Exclusion Criteria:
Patients who meet any of the following criteria will not qualify for participation in the trial:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Those subjects who have the AETOS implanted in the Primary Anatomic configuration
Device: AETOS
Those subjects who have AETOS implanted in the Reverse configuration
Device: AETOS
The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
Implant Survivorship
Implant survivorship at 2 years post operatively defined as absence of device removal or revision of any component
Time frame: 2 years
Implant Survivorship at 6 months, 1 year, 3.5 years and 5 years
Implant Survivorship at 6 months, 1 year, 3.5 years, and 5 years defined as absence of device removal or revision of any component
Time frame: 6 months, 1 year, 3.5 years, and 5 years
Radiographic Assessment - Glenoid Migration/Subsidence
Glenoid Component Migration / Subsidence collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of glenoid component displacement ≥ 5 mm relative to the native bone stock. 1. Present: Presence of glenoid component displacement ≥ 5 mm relative to the native bone stock.
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Glenoid Radiolucency
Glenoid Component Radiolucency - antero-posterior (AP) collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of radiolucency \> 2 mm in width along the bone-implant / bone-cement interface in any zone. 1. Present: Presence of radiolucency \> 2 mm in width along the bone-implant / bone-cement interface in one or more zones.
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Humeral Radiolucency
Humeral Component Radiolucency - AP collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of radiolucency \> 2 mm in width along the bone-implant interface in any zone. 1. Present: Presence of radiolucency \> 2 mm in width along the bone-implant interface in one or more zones.
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Humeral Migration/Subsidence
Humeral Component Migration / Subsidence collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Absent: No evidence of a change in position of the humeral component relative to the native bone stock ≥ 5 mm. 1. Present: Presence of a change in position of the humeral component relative to the native bone stock ≥ 5 mm
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Humeral Head Centeredness
Humeral Head Centeredness collected post-surgery at day 0, 1 year, 2 years, and 5 years will be calculated using the method described by Iannotti and Norris from the axillary view
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Bone Remodeling
Bone Remodeling of the humerus collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions by Schnetzke et al.: 0. Absent: No evidence of humerus bone remodeling. 1. Present: Presence of one or more features of humerus bone remodeling. * 1. Condensation Lines: Presence of condensation lines around the tip of the stem. * 2. Cortical Thinning: Presence of cortical thinning and osteopenia. * 3. Spot Welds: Presence of spot welds. * 4. Other: Other feature not listed above.
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Glenohumeral Subluxation
Glenohumeral Subluxation collected post-surgery at day 0, 1 year, 2 years, and 5 years will be will be derived from the Humeral Head Centeredness assessment using the following definitions, from Iannotti and Norris et al.: 0. Absent: Humeral Head Centeredness is ≤25%. 1. Present: Humeral Head Centeredness is \>25%.
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Device Condition: Anatomic
Device Condition - Anatomic collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Intact: No evidence of fracture, breakage, loosening, disassembly or migration of any of the components of the anatomic AETOS TSA. 1. Not Intact: Presence of fracture, breakage, loosening, disassembly or migration of one or more of the components of the anatomic AETOS TSA: * 1. Humeral Stem. * 2. Humeral Head. * 3. Glenoid. * 4. Post Extension.
Time frame: Day 0, 1 year, 2 years, and 5 years
Radiographic Assessment - Device Condition: Reverse
Device Condition - Reverse collected post-surgery at day 0, 1 year, 2 years, and 5 years will be graded in accordance with the following definitions: 0. Intact: No evidence of fracture, breakage, loosening, disassembly or migration of any of the components of the reverse AETOS TSA. 1. Not Intact: Presence of fracture, breakage, loosening, disassembly or migration of one or more of the components of the reverse AETOS TSA: * 1. Humeral Stem. * 2. Reverse Liner. * 3. Glenosphere. * 4. Metal Glenoid. * 5. Peripheral Screws. * 6. Central Screw. * 7. Humeral Spacer. * 8. Post Extension.
Time frame: Day 0, 1 year, 2 years, and 5 years
American Shoulder and Elbow Score (ASES)
The ASES instrument is composed of 2 sections containing participant self-reported and clinician assessments. The ASES score is a 0 to 100-point rating with a higher score indicating improvement in pain and function.
Time frame: 6 months, 1 year, 2 years, and 5 years
Constant Murley Score
Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology; two subjective: pain and activities of daily living (ADL) and two objective: range of motion (ROM) and strength. The subjective components can receive up to 35 points and the objective 65, resulting in a possible maximum total score of 100 points (best function). Pain and ADL are answered by the subject; ROM and strength require a physical evaluation and are answered by the orthopaedic surgeon or the physiotherapist.
Time frame: 6 months, 1 year, 2 years, and 5 years
Simple Shoulder Test (SST)
Series of 12 "yes" or "no" questions the patient answers about the function of the involved shoulder. The answer to these questions provides a standardized way of recording the function of a shoulder before and after treatment.
Time frame: 6 months, 1 year, 2 years, and 5 years
Single Assessment Numeric Evaluation (SANE)
The SANE is a simple, single-question, patient-based shoulder function assessment tool: ''How would you rate your shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?''
Time frame: 6 months, 1 year, 2 years, and 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Aug 2027, 41 months after the start.
Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's planned 41 months is below that.
Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.